Patents by Inventor Peter Hagedorn

Peter Hagedorn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20250136988
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: November 7, 2024
    Publication date: May 1, 2025
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, JR., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. MCDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
  • Antisense oligonucleotides targeting alpha-synuclein and uses thereof
    Patent number: 12241065
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 4, 2025
    Assignees: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
    Publication number: 20250051777
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Application
    Filed: October 28, 2024
    Publication date: February 13, 2025
    Inventors: Peter HAGEDORN, Anja Mølhart Høg, Marianne L. Jensen, Richard E. Olson
  • Antisense oligonucleotides targeting alpha-synuclein and uses thereof
    Patent number: 12180478
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: December 31, 2024
    Assignees: Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • Oligonucleotides for modulating Tau expression
    Patent number: 12163131
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: December 10, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Hagedorn, Anja Mølhart Høg, Marianne L. Jensen, Richard E. Olson
  • OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
    Publication number: 20240026360
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Application
    Filed: July 21, 2023
    Publication date: January 25, 2024
    Inventors: Peter HAGEDORN, Anja Mølhart HØG, Richard E. OLSON, Marianne L. JENSEN
  • Methods of selecting therapeutic molecules
    Patent number: 11761951
    Abstract: The present disclosure provides methods of using a calcium oscillation assay and/or a sequence score calculation to identify a molecule that is safe for administration. The disclosure also includes a method of selecting or identifying a molecule having tolerable in vivo neurotoxicity using a calcium oscillation assay, a sequence score method, an in vivo tolerability assay, or any combination thereof.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: September 19, 2023
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Niels Fisker Nielsen, Dong LI, Jeffrey M. Brown, Stephen E. Mercer, Marianne Lerbech Jensen
  • Oligonucleotides for modulating Tau expression
    Patent number: 11753640
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Grant
    Filed: December 31, 2020
    Date of Patent: September 12, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Hagedorn, Anja Mølhart Høg, Richard E. Olson, Marianne L. Jensen
  • Guanosine Analogues for Use in Therapeutics Polynucleotides
    Publication number: 20230212572
    Abstract: The present invention relates to a polynucleotide that comprises at least one phosphorothioate internucleoside linkage and at least one guanosine analogue comprising a guanine nucleobase analogue selected from the group consisting of: formula (I) and formula (II). Polynucleotides comprising such guanosine analogues show a relative reduced neurotoxicity compared to polynucleotides with natural guanosine.
    Type: Application
    Filed: June 8, 2021
    Publication date: July 6, 2023
    Inventors: Nanna Albaek, Peter Hagedorn, Mette Ladefoged, Lykke Pedersen, Jacob Ravn
  • ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20230193260
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: July 27, 2022
    Publication date: June 22, 2023
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. Cacace, Jere E. Meredith, JR., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • OLIGONUCLEOTIDES FOR SPLICE MODULATION OF CARD9
    Publication number: 20230193269
    Abstract: The present invention relates to splice modulating oligonucleotides (oligomers) that are complementary to the CARD9 pre-mRNA, for inhibiting the inclusion of a CARD9 exon 11 in CARD9 mRNA. The oligonucleotides of the invention are useful in the treatment of inflammatory diseases such as IBD.
    Type: Application
    Filed: May 22, 2020
    Publication date: June 22, 2023
    Inventors: Peter HAGEDORN, Lars JOENSON, Anja Moehart HOEG, Jonas VIKESSA, Fergus BYRNE, Jay FINE, Mouhamadou MBOW, Joe Adam WAHLE, Elliott Sanford KLEIN, Kristina Mary SAI, Fei SHEN
  • Antisense oligonucleotides targeting ATXN3
    Patent number: 11542501
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to ATXN3 pre-mRNA sequences, which are capable of inhibiting the expression of ATXN3 protein. Inhibition of ATXN3 expression is beneficial for the treatment of spinocerebellar ataxia.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: January 3, 2023
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Marianne Ravn Møller, Heidi Rye Hudlebusch, Lykke Pedersen, Erik Daa Funder, Christoffer Sondergaard, Jette Dam Hedegaard, Alexander Herbert Stephan, Peter Hagedorn
  • Oligonucleotides for modulating TMEM106B expression
    Patent number: 11485975
    Abstract: The present invention relates to oligonucleotides that are complementary to and modulate the expression of TMEM106B. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurological disorders using the oligonucleotide.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: November 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Peter Hagedorn, Marianne L. Jensen, Lukasz Kielpinski, Amy Easton, Benny Chih
  • Antisense oligonucleotides targeting alpha-synuclein and uses thereof
    Patent number: 11447775
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: September 20, 2022
    Assignees: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • ANGPTL2 ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
    Publication number: 20220213484
    Abstract: The present disclosure relates to antisense oligonucleotides, which target ANGPTL2 mRNA in a cell, leading to reduced expression of ANGPTL2 protein. Reduction of ANGPTL2 protein expression is beneficial for the treatment of certain medical disorders, such as those associated with abnormal ANGPTL2 expression and/or activity e.g., cardiovascular-related diseases or disorders.
    Type: Application
    Filed: April 2, 2020
    Publication date: July 7, 2022
    Inventors: Brian R. ANDERSON, Richard E. OLSON, Ivar M. MCDONALD, Stephen E. MERCER, Peter HAGEDORN, Marianne Lerbech JENSEN
  • Antisense oligonucleotides targeting alpha-synuclein and uses thereof
    Patent number: 11359197
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: June 14, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
    Publication number: 20220177884
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Application
    Filed: January 21, 2022
    Publication date: June 9, 2022
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Peter HAGEDORN, Anja Mølhart HØG, Marianne L. JENSEN, Richard E. OLSON
  • TAU ANTISENSE OLIGOMERS AND USES THEREOF
    Publication number: 20220143064
    Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: July 2, 2021
    Publication date: May 12, 2022
    Applicant: F. Hoffmann-La Roche AG
    Inventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Marianne Lerbech Jensen, Niels Fisker Nielsen, Dong Li, Jeffrey M. Brown, Stephen E. Mercer
  • ALPHA-SYNUCLEIN ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
    Publication number: 20220119811
    Abstract: The present disclosure relates to antisense oligonucleotides, which target Alpha-synuclein (SNCA) transcript in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder such as a synucleinopathy.
    Type: Application
    Filed: January 11, 2019
    Publication date: April 21, 2022
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Peter HAGEDORN, Richard E. OLSON, Angela M. CACACE, Marianne Lerbach JENSEN, Jeffrey M. BROWN, Jere E. MEREDITH, JR., Annapurna PENDRI, Ivar M. MCDONALD, Martin GILL
  • Oligonucleotides for modulating ATXN2 expression
    Patent number: 11286485
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of ATXN2 in a target cell. The oligonucleotides hybridize to ATXN2 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), Alzheimer's frontotemporal dementia (FTD), parkinsonism and conditions with TDP-43 proteinopathies using the oligonucleotide.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: March 29, 2022
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Peter Hagedorn, Dennis Jul Hansen, Heidi Rye Hudlebusch, Lykke Pedersen, Søren Vestergaard Rasmussen, Mette Ladefoged